Latest News for: interleukin 2

Edit

Coya Therapeutics Announces Positive Results of a Double Blind Study of Subcutaneous Low Dose Interleukin 2 (LD IL 2) in Alzheimer's Disease (AD) Presented at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid (Spain) Form 8 K (Coya Therapeutics Inc)

Public Technologies 29 Oct 2024
COYA 302 is comprised of proprietary low dose interleukin-2 (LD IL-2) and cytotoxic T lymphocyte-associated antigen 4 immunoglobulin fusion protein (CTLA-4 Ig) and is being developed for subcutaneous ...
Edit

Cue Biopharma�to Present at The Promise of Interleukin-2 Therapy Conference

Nasdaq Globe Newswire 03 Sep 2024
CUE), a clinical-stage biopharmaceutical company developing a novel class of ...
Edit

Medicenna Announces Upcoming Presentations at The Promise of Interleukin-2 Therapy Conference

Nasdaq Globe Newswire 27 Aug 2024
MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced ...
Edit

NK cells expressing interleukin-21 show promising antitumor activity in glioblastoma cells

Science Daily 13 Aug 2024
Natural killer (NK) cells engineered to express interleukin-21 (IL-21) demonstrated sustained antitumor activity against glioblastoma stem cell-like cells (GSCs) both in vitro and in vivo, according to new research ... .
Edit

Rani Therapeutics Announces Positive Topline Results From Phase 1 Study Of�An Oral Anti-Interleukin 12/23 Antibody (RT-111)

MENA FN 05 Feb 2024
(MENAFN - GlobeNewsWire - Nasdaq) - RT-111 achieved high bioavailability in humans - - RT-111 was well-tolerated, with no serious adverse events - - Celltrion has right of first negotiation to ... .
Edit

New Published Data Demonstrates Correlation Between Itch Cytokine Interleukin-31 Reduction and Pruritis Improvement in Primary ...

Victoria Advocate 03 Jan 2024
Seladelpar treatment reduces interleukin-31 and pruritus in patients with primary biliary cholangitis.
Edit

Almirall Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein ...

Business Wire 21 Dec 2023
ALM), a global pharmaceutical company focused on medical dermatology, today announced the initiation ...

Most Viewed

×